2-aminopyrimidine derivatives for the treatment of viral infections

• US 9,598,378 B2
• Filed: 02/20/2014
• Issued: 03/21/2017
• Est. Priority Date: 02/21/2013
• Status: Active Grant

• Current Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Original Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Inventors: McGowan, David Craig, Raboisson, Pierre Jean-Marie Bernard, Jonckers, Tim Hugo Maria
• Primary Examiner(s): RAO, DEEPAK R
• Application Number:
  US14/769,773
• Publication Number:
  US 20150376140A1
• Time in Patent Office: 1,125 Days
• Field of Search: 544/298, 514/272
• US Class Current: 1/1
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07D 239/47 One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• CPC Class Codes: C07D 239/48 Two nitrogen atoms

Abstract

This invention relates to 2-aminopyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Claims

1. A compound of formula (I)

2. A pharmaceutical composition comprising a compound of claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

3. A method of activating TLR7 and/or TLR8 to induce interferon-stimulated response elements in a subject in need thereof comprising administering to said subject at least one compound of claim 1.

4. The compound of claim 1, wherein

R₁ is hydrogen;

R₂ is methyl; and

n is 1.

5. The compound of claim 4, wherein

X is S.

6. The compound of claim 4, wherein

X is S═

O.

7. The compound of claim 4, wherein

X is O═

S═

O.

8. A compound selected from the group consisting of